发明名称 P27 AND P21 IN GENE THERAPIES
摘要 The expansion of a population of stem cells or progenitor cells, or precursors thereof, may be accomplished by disrupting or inhibiting p21<cip1/waf1> and/or p27, cyclin dependent kinase inhibitors. In the absence of p27 activity, progenitor cells move into the cell cycle and proliferate; whereas in the absence of p21 activity, stem cells move into the cell cycle and proliferate without losing their pluripotentiality (<i>i.e.</i>, their ability to differentiate into the various cell lines found in the blood stream). Any type of stem cell or progenitor cell, or precursor thereof, including, but not limited to, hematopoietic, gastrointestinal, lung, neural, skin, muscle, cardiac muscle, renal, mesenchymal, embryonic, fetal, or liver cell may be used in accordance with the invention. The present invention provides a method of expanding a cell population, cells with decreased p27 and/or p21 activity, transgenic animals with a disrupted p27 and/or p21 gene, pharmaceutical compositions comprising the cells of the invention, and methods of using these cells in gene therapy (<i>e.g.</i>, stem cell gene therapy) and bone marrow transplantation.
申请公布号 WO0166699(A3) 申请公布日期 2002.04.18
申请号 WO2001US07538 申请日期 2001.03.09
申请人 THE GENERAL HOSPITAL CORPORATION 发明人 SCADDEN, DAVID, T.;CHENG, TAO
分类号 A61K35/12;A61K48/00;C12N5/0789;(IPC1-7):C12N5/06;C12N15/10;C12N15/11;A01K67/027;A01H1/00 主分类号 A61K35/12
代理机构 代理人
主权项
地址